Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens
- 16 May 2025
- journal article
- research article
- Published by Springer Nature in Nature Cancer
- Vol. 6 (6) , 1073-1087
Abstract
Chimeric antigen receptor (CAR) T cell immunotherapy relies on CAR targeting of tumor-associated antigens; however, heterogenous antigen expression, interpatient variation and off-tumor expression by healthy cells remain barriers. Here we develop synthetic antigens to sensitize solid tumors for recognition and elimination by CAR T cells. Unlike tumor-associated antigens, we design synthetic antigens that are orthogonal to endogenous proteins to eliminate off-tumor targeting and that have a small genetic footprint to facilitate efficient tumor delivery to tumors by lipid nanoparticles. Using a camelid single-domain antibody (VHH) as a synthetic antigen, we show that adoptive transfer of anti-VHH CAR T cells to female mice bearing VHH-expressing tumors reduced tumor burden in multiple syngeneic and xenograft models of cancer, improved survival, induced epitope spread, protected against tumor rechallenge and mitigated antigen escape in heterogenous tumors. Our work supports the in situ delivery of synthetic antigens to treat antigen-low or antigen-negative tumors with CAR T cells.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (DP2-HD091793, DP1-CA280832, 5T32EB006343, F31-CA271803, 5T32EB006343, F31-CA271803, 5T32GM145735)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA273878)
- U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB032822)
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR000454)
- Shurl and Kay Curci Foundation (1S10OD016264-01A1)
- Wallace H. Coulter Department of Biomedical Engineering and the College of Engineering at Peking University
- National Science Foundation (DGE-1451512, DGE-1451512, DGE-1451512)
This publication has 79 references indexed in Scilit:
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T ImmunotherapiesCell, 2020
- Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapiesAnnals of Hematology, 2020
- Nanoparticles in the clinic: An updateBioengineering & Translational Medicine, 2019
- Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution ExperienceTransplantation and Cellular Therapy, 2019
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell TherapiesCNS Drugs, 2018
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell ResponsesCell, 2018
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing CircuitsCell, 2016
- A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence ImagingCell, 2014
- Extended presentation of specific MHC‐peptide complexes by mature dendritic cells compared to other types of antigen‐presenting cellsEuropean Journal of Immunology, 2004